Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1086 | 1010 | 1111 | 1077 | 1207 | 1500 |
Fund Return | 8.58% | 0.95% | 11.09% | 2.51% | 3.84% | 4.14% |
Place in category | 464 | 1146 | 871 | 394 | 344 | 263 |
% in Category | 38 | 81 | 67 | 33 | 34 | 43 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU1379517383 | 5.17B | -0.16 | 0.06 | - | ||
LU1313520857 | 5.17B | 0.35 | 0.66 | - | ||
LU1313520188 | 5.17B | 0.35 | 0.66 | - | ||
LU1379517110 | 5.17B | 0.18 | 0.46 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AllianzIncome Growth PM H2GBP | 50.16B | 8.13 | 0.49 | 6.18 | ||
AllianzIncome Growth AM H2GBP | 50.16B | 7.57 | -0.08 | 5.49 | ||
AllianzIncome Growth RM H2GBP | 50.16B | 8.10 | 0.51 | 6.15 | ||
JPMorgan GlblIncome A mth GBPHdgd | 17.66B | 9.33 | 1.45 | - | ||
JPMorgan GlblIncome C mth GBPHdgd | 17.66B | 10.05 | 2.16 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
UBS (Lux) BFConvert Eurp EUR U-X EUR Inc | LU0415180149 | 18.98 | - | - | |
UBS Lux Equity SICAV - European Opportunity Uncons | LU0549584711 | 17.70 | 41,687.580 | +0.23% | |
UBS(LUX) ES Eurp Hi DivSsEUR U-X-acc | LU0566497789 | 14.22 | - | - | |
UBS Lux Bond SICAV - Convert Global EUR I-X-dist | LU0396332644 | 14.21 | 186.200 | +0.02% | |
Teva Pharmaceutical Finance Netherlands II B.V 7.375% | XS2592804434 | 0.64 | - | - |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review